Production (Stage)
Eton Pharmaceuticals, Inc.
ETON
$14.30
-$0.21-1.45%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 116.95% | 59.26% | 46.90% | -24.36% | 50.19% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 116.95% | 59.26% | 46.90% | -24.36% | 50.19% |
| Cost of Revenue | 150.79% | 40.40% | 53.22% | 48.94% | 51.12% |
| Gross Profit | 96.94% | 78.40% | 43.13% | -41.89% | 49.64% |
| SG&A Expenses | 77.85% | 37.74% | 21.96% | 19.62% | -3.54% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 102.51% | 13.94% | 29.55% | 48.00% | 11.84% |
| Operating Income | 41.25% | 152.38% | 192.88% | -175.59% | 68.43% |
| Income Before Tax | -84.71% | 74.56% | 186.53% | -165.52% | 69.51% |
| Income Tax Expenses | -- | -64.78% | -- | -- | -- |
| Earnings from Continuing Operations | -93.83% | 73.49% | 208.29% | -166.70% | 69.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -93.83% | 73.49% | 208.29% | -166.70% | 69.51% |
| EBIT | 41.25% | 152.38% | 192.88% | -175.59% | 68.43% |
| EBITDA | 195.94% | 176.60% | 320.45% | -165.19% | 75.81% |
| EPS Basic | -85.71% | 73.86% | 207.56% | -166.25% | 69.77% |
| Normalized Basic EPS | -76.65% | 95.29% | 185.82% | -165.05% | 69.74% |
| EPS Diluted | -85.71% | 68.26% | 188.89% | -167.38% | 69.77% |
| Normalized Diluted EPS | -76.65% | 95.29% | 183.69% | -166.00% | 69.74% |
| Average Basic Shares Outstanding | 4.36% | 1.53% | 0.70% | 0.72% | 0.93% |
| Average Diluted Shares Outstanding | 4.36% | 1.53% | 3.23% | -0.79% | 0.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |